國家衛生研究院 NHRI:Item 3990099045/11407
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12340/13424 (92%)
造訪人次 : 1977752      線上人數 : 176
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11407


    題名: Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication
    作者: Yeo, YH;Hsu, CC;Lee, CC;Ho, HJ;Lin, JT;Wu, MS;Liou, JM;Wu, CY;Taiwan Gastrointestinal Disease and Helicobacter Consortium
    貢獻者: Institute of Population Health Sciences
    摘要: BACKGROUND AND AIM: The eradication rate of Helicobacter pylori has been declining over the past decades. A rescue plan is needed for increasing populations with treatment failure. However, the optimum second-line eradication regimen remains inconclusive. We conducted a network meta-analysis to assess the comparative effectiveness of second-line Helicobacter pylori (H. pylori) eradication therapies and determine the optimum regimen. METHODS: We searched electronic databases from January 2005 to Feb 2018 for randomized controlled trials assessing the effectiveness of second-line regimens in patients with persistent H. pylori infection after first-line treatment. Bayesian network meta-analysis (NMA) was performed to combine the direct and indirect evidence and to investigate the rank order of second-line therapies. We also appraised the quality of evidence using GRADE guidance. RESULTS: Twenty-six trials with 3,628 participants who received second-line eradication therapy were identified. All regimens showed pooled eradication rates <90%. Compared with 7-day triple therapy, quinolone-based (odds ratio [OR] 4.29, 95% credible interval [CrI] 1.67-12.12, SUCRA 0.95) and non-quinolone-based bismuth-containing quadruple therapies for 10 days or more (OR 2.25, 95% CrI 1.10-4.62, SUCRA 0.78) and sequential therapy (OR 2.91, 95% CrI 1.16-7.65, SUCRA 0.66) showed significantly higher effectiveness. Overall, regimens with longer duration demonstrated higher eradication rates but higher rates of adverse events. More adverse events were reported in those patients treated with concomitant therapy. CONCLUSIONS: Quinolone-based bismuth-containing quadruple therapies for 10 days or more are the optimum regimens for H. pylori eradication.
    日期: 2019-01
    關聯: Journal of Gastroenterology and Hepatology. 2019 Jan;34(1):59-67.
    Link to: http://dx.doi.org/10.1111/jgh.14462
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0815-9319&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000455896500012
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85054826093
    顯示於類別:[林肇堂] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB30169908.pdf1228KbAdobe PDF124檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋